Polyendocrine Metabolic Ovarian Syndrome (PMOS),Formerly Known as Polycystic Ovary Syndrome (PCOS)

 

Polyendocrine Metabolic Ovarian Syndrome (PMOS)

Formerly Known as Polycystic Ovary Syndrome (PCOS)

PMOS, or Polyendocrine Metabolic Ovarian Syndrome, is the newly adopted medical term for the condition historically known as PCOS (Polycystic Ovary Syndrome). The terminology shift was proposed and endorsed by international endocrine and gynecologic experts in 2026 to better reflect the multisystem endocrine and metabolic nature of the disease rather than focusing narrowly on ovarian “cysts.”

Abstract

Polyendocrine Metabolic Ovarian Syndrome (PMOS) is one of the most common endocrine disorders affecting women of reproductive age. Traditionally termed Polycystic Ovary Syndrome (PCOS), the condition has undergone conceptual and nomenclature revision due to increasing recognition that it is not merely an ovarian disorder but a complex multisystem metabolic-endocrine disease involving reproductive, metabolic, cardiovascular, dermatologic, and psychological manifestations. PMOS affects approximately 8–13% of reproductive-aged women worldwide, although a substantial proportion remain undiagnosed. Insulin resistance, hyperandrogenism, chronic low-grade inflammation, neuroendocrine dysregulation, and ovarian dysfunction are central to its pathophysiology. Clinical manifestations include menstrual irregularities, infertility, obesity, hirsutism, acne, metabolic syndrome, type 2 diabetes mellitus, and cardiovascular risk. This review discusses updated concepts in pathogenesis, clinical features, diagnosis, investigations, complications, and evidence-based management strategies for medical students and healthcare professionals.

Introduction

PMOS is a heterogeneous endocrine-metabolic disorder characterized by:

• Ovulatory dysfunction
• Hyperandrogenism
• Polycystic ovarian morphology
• Metabolic abnormalities

The condition is now recognized as a lifelong systemic disease rather than a purely gynecological condition. The renaming to PMOS emphasizes:

• Polyendocrine → involvement of multiple hormonal systems
• Metabolic → insulin resistance and metabolic syndrome
• Ovarian → reproductive dysfunction remains important
• Syndrome → heterogeneous clinical manifestations

The name change emerged after more than a decade of international consensus-building among endocrine societies and patient advocacy groups.

Epidemiology   

• Major cause of anovulatory infertility

Higher prevalence occurs among:

• Obese individuals
• Those with family history
• Sedentary lifestyle populations
• Insulin-resistant phenotypes

Indian studies suggest particularly high prevalence among urban adolescents and young women due to:

• Sedentary lifestyle
• Dietary transition
• Obesity
• Stress-related hormonal dysregulation

Etiology

The exact etiology remains incompletely understood. PMOS is considered a multifactorial disorder involving:

1. Genetic Factors

• Familial clustering common
• Polygenic inheritance pattern
• Candidate genes:
• INSR
• CYP11A
• CYP17
• FSH receptor genes
• LH receptor genes

2. Insulin Resistance

Central pathogenic factor in many patients.

Hyperinsulinemia:

• Stimulates ovarian androgen production
• Suppresses hepatic SHBG synthesis
• Increases free testosterone levels

3. Neuroendocrine Dysfunction

Increased GnRH pulsatility causes:

• ↑ LH secretion
• Relative ↓ FSH secretion

Result:

• Excess androgen production
• Arrested follicular maturation

4. Obesity and Adipose Dysfunction

Visceral adiposity promotes:

• Insulin resistance
• Chronic inflammation
• Altered adipokines
• Hyperandrogenism

5. Environmental Factors

• Sedentary lifestyle
• High-calorie diets
• Endocrine disruptors
• Chronic stress
• Sleep disorders

Detailed Pathophysiology

Central Pathophysiologic Mechanisms

PMOS develops through interaction among:

1. Insulin resistance
2. Hyperandrogenism
3. Ovarian dysfunction
4. Neuroendocrine abnormalities
5. Inflammation

1. Insulin Resistance and Hyperinsulinemia

A major hallmark of PMOS.

Mechanism

Peripheral tissues become resistant to insulin:

• Skeletal muscle
• Adipose tissue
• Liver

Result:

• Compensatory hyperinsulinemia

Insulin then acts synergistically with LH on ovarian theca cells.

Consequences

• ↑ Androgen synthesis
• ↓ Sex hormone-binding globulin (SHBG)
• ↑ Free testosterone
• Follicular arrest
• Anovulation

2. Hyperandrogenism

Excess androgen production originates mainly from:

• Ovarian theca cells
• Adrenal glands

Major androgens:

• Testosterone
• Androstenedione
• DHEAS

Clinical effects:

• Hirsutism
• Acne
• Alopecia
• Menstrual dysfunction

3. Ovarian Dysfunction

Follicular maturation arrests at small antral follicle stage. This causes:

• Chronic anovulation
• Infertility
• Accumulation of immature follicles

These are mistakenly termed “cysts.”

4. Hypothalamic-Pituitary Dysfunction

Increased GnRH pulse frequency preferentially stimulates LH secretion.

Result: Increased LH : FSH ratio, LH:FSH Ratio>2:1

Elevated LH stimulates androgen synthesis. Reduced FSH impairs follicular maturation.

5. Chronic Low-Grade Inflammation

Patients often demonstrate elevated:

• CRP
• TNF-α
• IL-6

Inflammation worsens:

• Insulin resistance
• Endothelial dysfunction
• Cardiovascular risk

6. Adipokine Dysregulation

Altered adipose hormones:

• ↓ Adiponectin
• ↑ Leptin
• ↑ Resistin

Contributes to:

• Metabolic syndrome
• Obesity
• Diabetes risk

Clinical Features

Presentation varies considerably.

Menstrual Symptoms

• Oligomenorrhea
• Amenorrhea
• Irregular cycles
• Heavy bleeding

Hyperandrogenic Symptoms

• Hirsutism
• Acne
• Seborrhea
• Androgenic alopecia

Reproductive Features

• Anovulatory infertility
• Recurrent miscarriages
• Delayed conception

Metabolic Features

• Central obesity
• Insulin resistance
• Acanthosis nigricans
• Dyslipidemia

Psychological Features

• Anxiety
• Depression
• Eating disorders
• Reduced quality of life

Recent literature strongly emphasizes the psychological burden of PMOS.

Diagnostic Criteria

Rotterdam Criteria (Most Widely Used)

Diagnosis requires 2 out of 3:

1. Hyperandrogenism

Clinical or biochemical

2. Ovulatory Dysfunction

• Oligo-ovulation
• Anovulation

3. Polycystic Ovarian Morphology

Ultrasound findings:

• ≥20 follicles
• Increased ovarian volume

Diagnostic Workup

Laboratory Tests

Hormonal Profile

• Total testosterone
• Free testosterone
• DHEAS
• LH
• FSH
• Prolactin
• TSH

Metabolic Assessment

• Fasting glucose
• HbA1c
• Lipid profile
• Oral glucose tolerance test

Imaging

Pelvic Ultrasound

Typical appearance:

• Multiple peripheral follicles
• “String of pearls” appearance

Differential Diagnosis

Important exclusions:

• Congenital adrenal hyperplasia
• Cushing syndrome
• Hyperprolactinemia
• Hypothyroidism
• Androgen-secreting tumors
• Hypothalamic amenorrhea

Complications

Short-Term

• Infertility
• Menstrual abnormalities
• Acne
• Hirsutism

Long-Term

Metabolic

• Type 2 diabetes mellitus
• Metabolic syndrome
• NAFLD

Cardiovascular

• Hypertension
• Dyslipidemia
• Atherosclerosis

Reproductive

• Endometrial hyperplasia
• Endometrial carcinoma

Psychological

• Depression
• Anxiety
• Body-image disorders

PMOS and Infertility

PMOS is the leading cause of anovulatory infertility.

Mechanism:

• Failure of dominant follicle maturation
• Chronic anovulation
• Poor oocyte quality

Many women still achieve successful pregnancy with proper management.

Treatment and Management

Management is individualized according to:

• Fertility goals
• Metabolic risk
• Symptom severity
• Age

1. Lifestyle Modification

First-line therapy for all patients.

Weight Reduction

Even 5–10% weight loss improves:

• Ovulation
• Insulin sensitivity
• Menstrual regularity
• Fertility

Diet

Recommended:

• Low glycemic index diet
• Mediterranean diet
• High-fiber intake
• Reduced refined carbohydrates

Exercise

• ≥150 minutes/week moderate exercise
• Resistance training beneficial

2. Pharmacologic Therapy

A. Combined Oral Contraceptives (COCs)

First-line for:

• Menstrual regulation
• Acne
• Hirsutism

Mechanism:

• ↓ LH secretion
• ↑ SHBG
• ↓ Free testosterone

B. Anti-Androgens

Spironolactone

Used for:

• Hirsutism
• Acne

Requires contraception due to teratogenicity.

C. Insulin Sensitizers

Metformin

Major drug in PMOS management.

Mechanism:

Insulin Resistance↓⇒Androgen Production↓

Benefits:

• Improves insulin sensitivity
• Restores ovulation
• Reduces androgen levels
• Assists weight reduction

3. Ovulation Induction

For infertility treatment.

Letrozole (Current First-Line)

Aromatase inhibitor.

Superior live birth rates compared with clomiphene.

Clomiphene Citrate

Traditional ovulation induction agent.

Gonadotropins

Used in resistant cases.

Risk:

• Ovarian hyperstimulation
• Multiple pregnancy

4. Surgical Therapy

Laparoscopic Ovarian Drilling

Reserved for:

• Resistant anovulation

Mechanism:

• Reduces androgen-producing tissue

5. Emerging Therapies

GLP-1 Receptor Agonists

Examples:

• Semaglutide
• Liraglutide

Benefits:

• Weight loss
• Improved insulin sensitivity
• Metabolic improvement

Psychological Management

Essential but often overlooked.

Includes:

• Counseling
• Cognitive behavioral therapy
• Psychiatric support
• Eating disorder screening

Prevention Strategies

Although complete prevention is not established:

Risk reduction includes:

• Healthy body weight
• Regular exercise
• Balanced diet
• Early screening in at-risk adolescents

Prognosis

PMOS is chronic but manageable.

Early diagnosis and intervention improve:

• Fertility outcomes
• Metabolic health
• Cardiovascular risk
• Quality of life

Untreated disease may progress to:

• Diabetes
• Cardiovascular disease
• Endometrial pathology

Future Directions

Current research focuses on:

• Precision medicine
• Genetic biomarkers
• Gut microbiome
• Novel insulin sensitizers
• Anti-inflammatory therapies

The renaming to PMOS may improve:

• Public awareness
• Early diagnosis
• Multidisciplinary treatment
• Research funding

Key Points for Medical Students

• PMOS is the new term for PCOS.
• It is a multisystem endocrine-metabolic disorder.
• Insulin resistance is central to pathogenesis.
• Hyperandrogenism causes most clinical manifestations.
• Rotterdam criteria remain the diagnostic standard.
• Lifestyle modification is first-line treatment.
• Letrozole is first-line ovulation induction therapy.
• Long-term monitoring for diabetes and cardiovascular disease is essential.

Conclusion

Polyendocrine Metabolic Ovarian Syndrome (PMOS) represents a paradigm shift in understanding one of the most common endocrine disorders in women. The updated terminology reflects the systemic nature of the disease and emphasizes its metabolic and endocrine complexity beyond ovarian pathology. Insulin resistance, hyperandrogenism, inflammation, and neuroendocrine dysfunction collectively drive reproductive and metabolic abnormalities. Early recognition and comprehensive management are crucial to reducing long-term complications and improving reproductive, metabolic, and psychological outcomes.

Selected References

1. International evidence-based guideline for PCOS/PMOS
2. Endocrine Society Clinical Practice Guidelines
3. Rotterdam ESHRE/ASRM Consensus Criteria
4. The Lancet Consensus on PMOS nomenclature (2026)
5. American College of Obstetricians and Gynecologists (ACOG)
6. European Society of Human Reproduction and Embryology (ESHRE)

…………………………………………………………………………………